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Abstract  
Aims To estimate the prevalence of self-reported pharmacological neuroenhancement (PNE) with prescription or 
recreational drugs among the Swiss general population and correlates of PNE. Design A population-based cross-
sectional study using a self-administered online survey. Setting A telephone-recruited highly representative 
Internet Panel in Switzerland. Participants A total of 10 171 Swiss employees and students (unweighted N = 10 
084) aged 15 to 74 years (mean age: 39.1 ± 13.3; 46.6% female). Measurements Self-reported lifetime, past-
year, and past-month use of prescription or recreational drugs for PNE, motives for use, and correlates of PNE 
including socio-demographic, health, and recreational drug use characteristics. Findings The lifetime prevalence 
of PNE was 4.0% (95% CI = 3.62, 4.38), and the past-year prevalence was 2.1% (95% CI = 1.82, 2.38). Lifetime 
pharmacological mood enhancement (3.1%; 95% CI = 2.76, 3.44) was more prevalent than pharmacological 
cognitive enhancement (1.4%; 95% CI = 1.17, 1.63). Fifty-four participants reported both (0.5%; 95% CI = 0.36, 
0.64). PNE was associated with studying rather than full-time (OR = 0.35; 95% CI = 0.21, 0.57) or part-time 
employment (OR = 0.39; 95% CI = 0.23, 0.67), stress (OR = 1.51 95% CI = 1.31, 1.75), cocaine (OR = 2.40; 
95% CI = 1.51, 3.82) and amphetamine use (OR = 2.44; CI 95% = 1.37, 4.33), diagnosis of a mental disorder 
(OR = 4.26; 95% CI = 3.14, 5.80), and perceived poor health (OR = 0.76; 95% CI = 0.64, 0.90). Conclusions 
Pharmacological neuroenhancement was rare among Swiss employees and students (4.0%). Pharmacological 
mood enhancement (3.1%) is more prevalent than direct cognitive enhancement (1.4%).  
 
Key reference terms 
Pharmacological neuroenhancement; cognitive enhancement; mood enhancement; nonmedical prescription drug 
use; illegal drug use 
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Introduction 
The use of prescription or recreational drugs by healthy individuals to enhance cognitive or affective function 
[1,2] is termed pharmacological neuroenhancement (PNE) when explicitly used for the purpose of improved 
performance at work or in education [3]. Prescription drugs indicated for the treatment of psychiatric disorders 
such as attention-deficit hyperactivity disorder (ADD/ADHD) or narcolepsy are the focus of the PNE debate 
because these drugs also have cognitive-enhancing effects in healthy individuals [1,4].  
The prevalence of nonmedical stimulant use is well researched among American college students 
although differentiation of motives for use is often lacking [5–9].  While the estimated annual prevalence of drug 
use for PNE was 4.0% [10], estimated nonmedical use ranged from 1.5% to 35% [11,12]. The most recent and 
most comprehensive review estimated the rate of prescription stimulant misuse among college students at 17.0% 
[13]. Table 1 provides an overview of recently published studies estimating specifically the prevalence of PNE 
among different study samples and different substances used to improve performance at work or while studying.  
 
(Table 1) 
 
Several recent studies have concluded that the use of psychoactive substances for cognitive 
enhancement among students is less prevalent in Europe than in the United States [3,14–17]. Three Swiss studies 
have addressed the prevalence of PNE among students and young Swiss men and reported a lifetime prevalence 
of PNE of 3.0% to 13.8% but only rare current regular use [18–20]. The highest prevalence rate was, however, 
due to the inclusion of the recreational drugs alcohol and cannabis, which were not only used recreationally 
(90.2% and 43.3%, respectively) but also to improve study performance (5.6% and 2.5%, respectively) [20]. 
Swiss students reported the use of illegal stimulant mainly for recreation (MDMA= 5.2%, cocaine = 4.2%, and 
amphetamine = 3.7%) and rarely to enhance study performance (all < 0.5%) [20] Consistent with previous 
research [9], all of the Swiss studies observed a positive association between recreational drug use and PNE [18–
20]. However, the study estimating the prevalence of PNE among young Swiss men is not included in Table 1 
because of a lacking predefinition of the purpose of illicit drug use [19].Despite an increasing number of 
research publications on PNE, the generalizability of the research results is problematic because the inclusion of 
substances used for PNE differs greatly among studies [3,21]. Furthermore, the distinction between medical use 
and nonmedical use is often not clear. In general, the 12-month prevalence  of prescription stimulant use in the 
Swiss population is low (0.5%) and most prevalent among youth and young adults [22]. Past-year use of sedative 
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prescription drugs is more prevalent (9.7%) and associated with female gender and increased age [22]. Although 
the source of supply was specified, nonmedical use was not further specified. 
Interpreting the results for the prevalence of PNE is also complicated by differences among countries in 
the approval of medication for the treatment of mental health disorders. Moreover, users are often not aware of 
the trade names of prescription drugs, and this lack of awareness may bias the outcome of the prevalence of 
prescription drug use in surveys. A substantial advantage of online surveys is the presentation of pictures of 
putatively enhancing drugs to facilitate the recognition of the drugs that have been used [23]. The present study 
is the first in Europe on the topic of PNE to combine questions about the prevalence of the use of prescription 
and over-the-counter drugs with pictures of the pills, blister, and packaging. In addition, previous studies of the 
prevalence of and attitudes toward PNE have focused primarily on vulnerable groups, such as students 
[5,8,16,24], scientists [25], physicians [26], and pilots [27,28], but never on the general population.  
This study was designed 1) to estimate the prevalence of PNE among employees and students in 
Switzerland considering different motives for use; 2) to identify relevant substances used for direct cognitive 
enhancement (PCE) or increased psychological well-being and mood enhancement (PME); and 3) to investigate 
the differences between people experienced with PNE and non-users to reveal potential predictors for PNE. 
 
Materials and methods 
Participants and enrollment procedure  
Participants were drawn from a representative Internet panel of the LINK institute for market and social research 
in Switzerland, which consists of more than 130 000 people living in Switzerland who consented to be contacted 
for public opinion surveys administered through the Internet. The LINK institute uses a computer-assisted 
telephone interviewing system to recruit panelists representing the Swiss general public. These panelists are 
representative of the 15- to 74-year-old population of Switzerland that uses the Internet at least once per week 
for private purposes and is able to answer a questionnaire in German, French, or Italian. The study was 
conducted during March 2013, and participants were rewarded with one of the following incentives, equal to a 
value of approximately 2 Euros: points for supermarkets, bookshops, or donation campaigns.  
A total of 39 996 e-mail invitations were sent out, and 18 094 began the survey, corresponding to 
approximately 45.2% of the invitations. Of the 18 094 panelists who responded, 12 404 met the eligibility 
criteria (currently employed or in education and quota not yet fulfilled) for the study. A total of 10 084 (82.3%) 
completed the survey; 2320 (18.7%) did not complete the survey (see participant flow diagram; Fig. 1). 
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(Fig. 1) 
 
The self-reported data on PNE and correlates were weighted for age, gender, and language region to create 
national-level estimates of the prevalence of neuroenhancement. The definition of quota cells for the sample was 
based on the data for the constant resident population of Switzerland (STATPOP) published by the Federal 
Statistical Office. Informed consent was obtained from all participants included in the study. The final weighted 
sample referred to in the present paper consisted of 10 171 participants; the number of interviews realized per 
quota cell and the resulting weighting factor for the data for each language region in Switzerland are provided in 
the supplementary materials (Table S1).  
 
Outcome measures 
A self-administered online questionnaire based on previous surveys of substance use at work or while studying 
was used to estimate the prevalence of PNE as well as important correlates such as socio-demographic data, 
stress, and physical and mental health; the specifications of the questionnaire design are provided in the 
supplementary materials (Methods S1). The questionnaire was pretested with 103 participants of the LINK 
Internet panel and improved accordingly.  
Participants were asked whether they were aware of PNE and whether they knew other people using 
prescription or recreational drugs intentionally to enhance cognition or mood at work or while studying. The 
prevalence of and the two main motives for PNE at work or for studying were examined through two principal 
questions. First, participants were asked whether they had ever used prescription or recreational drugs to enhance 
their cognitive performance at work or while studying. Second, they were asked whether they had ever used 
prescription or recreational drugs to enhance their mood at work or while studying. The group of people who 
answered affirmatively to at least one of these two questions will be referred to as PNE users hereafter. 
Cognitive and mood enhancement were the two main motives of interest, but all participants were required to 
indicate for each substance used whether the use was aimed at specific neuroenhancement purposes: to enhance 
concentration, alertness, and vigilance; to reduce nervousness; to enhance mood at work or while studying; and 
to relax after stress at work or in education. 
 
Statistical analysis 
Descriptive statistics provided information about the prevalence and substances used for PNE; the prevalence of 
the use of alcohol, illegal drugs, and legally available soft enhancers; the frequency of stress; and the physical 
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and mental health states of the participants. Initially, we performed separate logistic regression analyses 
(subsequently termed ‘univariate analyses’) to evaluate the ability of each independent variable to predict the 
lifetime use of PNE. All predictors from the univariate analyses were entered into a fully adjusted multivariable 
model. Nagelkerke’s R-square was calculated as a goodness-of-fit measure for the multivariable model. All 
quantitative analyses were conducted using IBM SPSS Statistics Version 22 (SPSS Inc., Chicago, IL, USA). 
Significance was set at P < 0.050.  
 
Results 
Participant characteristics 
The stratified sample displayed an equal distribution of gender (46.5% female) and a mean age of 39.1 years (SD 
= 13.3). The majority of participants were German-speaking and worked full- or part-time. Three of four 
participants (71.6%) were aware of PNE. One-quarter of the sample was aware of one (14.3%) or more (11.5%) 
people in their circle of acquaintances who had used prescription or recreational drugs at least once to enhance 
their cognitive performance (PCE) at work or while studying. One fifth of the participants, however, knew one 
(11.6%) or more (8.2%) people who had used psychoactive substances to increase psychological well-being 
(PME) at work or while studying. Participants who knew at least one PNE user (35.0%) were seven times more 
likely to report own experiences of PNE (OR = 7.03; 95% CI 5.55, 8.90). Moreover, a small number of 
participants reported that their friends had already recommended PCE (4.3%) or PME (2.3%) to them. A narrow 
majority of the sample did not recognize any justification for PNE (57.7%), and only a few people were willing 
to use prescription drugs (8.7%) or recreational drugs (4.0%) to improve their performance at work or while 
studying, even if the hypothetical case that the drugs were effective was true. Furthermore, the majority of the 
participants believed that the use of prescription and recreational drugs for PNE might be harmful (74.3% and 
85.3%, respectively). 
 
Prevalence of PNE 
The participant characteristics for the analysis of lifetime PNE are presented in Table 2. Of the study 
participants, 4.0% (n = 411; 95% CI = 3.62, 4.38) reported the use of prescription or recreational drugs to 
perform better at work or while studying (PNE). Lifetime PME to perform better at work or while studying 
(3.1%; 95% CI = 2.76, 3.44) was more prevalent than PCE (1.4%; 95% CI = 1.17, 1.63) Fifty-four participants 
reported both (0.5%; 95% CI = 0.36, 0.64). The past-year prevalence of PNE was 2.1% (n = 215; 95% CI = 1.82, 
2.38).  
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Univariate predictors of lifetime PNE 
As shown in Table 2, all variables were univariate predictors of lifetime PNE. 
 
(Table 2)   
 
The lifetime use of recreational drugs and soft enhancers as univariate predictors for PNE is displayed in Table 
3. The lifetime use of tobacco, illegal drugs, and over-the-counter (OTC) drugs was more prevalent among PNE 
users. No association was observed for lifetime use of alcohol and caffeine products. Only a few people reported 
the use of a fictitious drug; these individuals were, for the most part, not experienced with PNE (Table 3). 
 
(Table 3) 
 
Multivariable predictors of lifetime PNE 
The overall prediction model resulting from a hierarchical logistic regression (R
2
 = 0.27) is presented in Table 4 
and revealed that the following variables were positively associated with lifetime PNE: being a student, frequent 
stress in the past 12 months, psychological consulting, lifetime diagnosis of a mental disorder, and lifetime use 
of cocaine and illegal amphetamine. Having minor children at home and perceived health were negatively 
associated with lifetime PNE. 
 
(Table 4) 
 
Prescription drugs used for PNE, motives for use, and source of supply 
Tranquilizers and antidepressants were the substances most commonly misused, and current prescription drug 
misuse within the past 30 days was rare for all prescription drug categories (Table 5). Among PNE users, 26.2% 
reported lifetime nonmedical use of tranquillizers, 20.2% antidepressants, 14.2% ADD/ADHD medication, 3.5% 
beta-blockers, 1.8% modafinil, and 0.4% anti-dementia drugs. The prevalence of nonmedical use of each 
medication evaluated in the survey is available in the supplementary materials (Table S2). The source of supply 
for the nonmedical use of prescription drugs was most commonly a doctor (Table 5). However, the main source 
of supply for ADD/ADHD medication was friends (Table 5). A narrow majority of the PNE users reported the 
desired effects of PNE with prescription drugs (Table 5). 
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(Table 5) 
 
The reported nonmedical use of tranquilizers was aimed mainly at improving sleep and relaxation after stress at 
work or in education (33.5%). The main motive for the nonmedical use of antidepressants was PME at work or 
while studying (58.8%) as well as PME in leisure (38.3%). ADHD medications were most commonly misused 
for PCE (74.5%). The only two people who mentioned the misuse of an anti-dementia drug both used the drug 
for the purpose of PCE. The number of participants who used modafinil and beta-blockers without having a 
prescription or other than prescribed was too small to make reliable statements about the motives for use.  
 
Recreational drugs used for PNE, motives for use, and source of supply 
Alcohol users mentioned relaxation during leisure time as their most important motive for drinking alcohol. 
Partying and getting high were the main motives for the use of illegal drugs (87.4% for MDMA, 77.7% for 
cocaine, 73.2% for illegal amphetamine, 59.2% for ketamine, 54.7% for cannabis) except for GHB/GBL, for 
which half of the self-named users reported that their use occurred involuntarily. However, 15.2% of illegal 
amphetamine and 11.6% of cocaine users reported that they had already used these drugs intentionally for PCE 
(Table 5). Moreover, the use of alcohol and cannabis to relax and to calm down after stress in the workplace or 
education, which would be considered indirect PNE [3], was reported by one quarter of alcohol users and one 
fifth of cannabis users (Table 6). 
 
(Table 6) 
 
The main source of supply for illegal drugs was the circle of friends (91.3% for cannabis, 80.8% for MDMA, 
78.7% for illegal amphetamine, 78.0% for cocaine, 69.3% for ketamine, 57.7% for GHB/GBL) and, less 
commonly, a dealer (41.9% for GHB/GBL, 33.7% for ketamine, 32.9% for MDMA, 29.1% for cocaine, 27.6% 
for illegal amphetamine, 14.6% for cannabis). Only a minority of users had bought their drugs on the Internet 
(15.9% for ketamine, 5.9% for GHB/GBL, 2.0% for illegal amphetamine, 0.9% for cocaine, 0.7% for MDMA, 
0.5% for cannabis) or received them from family members (9.4% for ketamine, 5.2% for GHB/GBL, 3.0% for 
cannabis, 2.1% for illegal amphetamine, 2.2% for cocaine, 1.1% for MDMA).  
 
Discussion 
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This study is the first representative large-scale study of PNE among the Swiss population that did not focus 
solely on students but also on employees and surveyed the various substances used for PNE. The study revealed 
three main findings. 1) Among the study sample, 4.0% reported lifetime use of prescription or recreational drugs 
for PNE, but only half of these respondents (2.1%) reported PNE within the past year. 2) Lifetime diagnosis of a 
mental disorder, experience with professional psychological consulting, stress, being a student, living without 
minor children at home, perceived poor health, and the lifetime use of the illegal stimulants cocaine and 
amphetamine were the strongest predictors of lifetime PNE. 3) PME was more prevalent than PCE or both 
PME/PCE.  
According to our study, the lifetime and 12-month prevalence rates of PNE were rather low compared 
to other studies (see Table 1) or general prescription and recreational drug in the Swiss population [22,29]. This 
result is consistent with recent research on substance use for PNE among German and Swiss employees [30–32] 
but indicates a lower prevalence compared to Swiss student-only surveys [18,20]. The willingness to use 
prescription drugs or recreational drugs for PNE for the hypothetical case that they were effective without any 
side effects was considerably low among study participants without self-reported PNE (8.7% and 4.0%, 
respectively). However, the interest in PNE was slightly higher  among students, demonstrating the need to 
monitor PNE among youth in Europe. The authors of a recent study of PNE among UK students claimed that the 
low prevalence despite high interest might be explained by the lack of availability of prescription drugs [33]. 
Participants who reported a lifetime diagnosis of a mental disorder were more than four times more 
likely to report PNE. Moreover, participants who felt often or very often stressed during the past 12 months and 
participants who rated their health as only poor were also more likely to report PNE. Having minor children at 
home was found to be a protective factor that made the occurrence of PNE unlikely. The association between 
illegal drug use and PNE established in the literature [6,9,20,34] was confirmed in the present study. Participants 
who reported having used cocaine or illegal amphetamine were more than two times more likely to report PNE. 
The nonmedical use of antidepressants and tranquilizers for increased well-being (PME) was more 
prevalent than stimulant use for cognitive enhancement. Furthermore, the majority of PME users had previously 
sought help because of a mental health problem and were assumed to misuse their current or past medication for 
PNE [7,35]. The finding that the participants reported greater awareness of PCE by others (25.8%) compared to 
PME by others (19.8%), although opposite prevalence rates of substance use for these purposes were reported, 
potentially indicating underreporting of PCE in the present study. In addition, the use of sedating substances, 
such as alcohol and cannabis, to relax after stress in the workplace or education was more common than illicit 
stimulant use for PCE and can be viewed as a form of indirect PCE if used to increase relaxation to perform 
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better the next day [3]. The frequent and high use of alcohol (and/or cannabis) as a socially accepted strategy to 
cope with stress may cause greater harm than occasional PCE with prescription drugs during short periods in 
life. However, further studies are needed to determine if PCE use by students continues after graduation. 
 
Strengths, limitations and implications 
A major strength of this study is the large sample of employees and students recruited as part of the Swiss 
national Internet panel of the LINK institute, which is representative of the Swiss population. Furthermore, 
thorough weighting procedures were used to investigate substance use for the purpose of cognitive and mood 
enhancement at work or while studying. Moreover, this survey included authentic photos of each medication to 
facilitate user recognition and inquired specifically about nonmedical use and its motives. In addition, two 
fictitious drugs were included to control for socially desirable responding behavior. 
However, the ability of the Internet panel to provide representative data may be questioned. Do only 
middle-class Swiss people with good jobs and a good social context participate in these surveys? Could PNE be 
underestimated in Switzerland because the stressed population who requires enhancement does not have time to 
occasionally participate in surveys for an Internet panel? What type of student is likely to engage in an additional 
Internet panel for surveys if already flooded with invitations to participate in research studies at their higher 
education institution? 
A further limitation is the formulation of the question about PNE. The two main questions asked about 
participants’ use of prescription and recreational drugs to perform better at work or while studying. Most of the 
participants had most likely not considered indirect enhancement with sedating substances for PNE when 
responding to questions about substance use for performance. Therefore, a more specific definition of PNE 
should be implemented in subsequent surveys [3]. In addition, we asked about a broad range of potential 
prescription drugs used for PNE (Table S2) but did not address the issue of generic medication. 
The identification of two different types of PNE users with different motives for substance use has 
several implications for preventing physical and mental harm. First, healthy PNE users without a current or past 
mental disorder should be informed about the possible risks and side effects of PNE use. Academic institutions 
and companies could provide students and employees with information about strategies other than substance use 
and develop stress-management training as tools for early prevention of PNE in healthy individuals. Moreover, 
increased communication about the addiction potential of certain drugs used for PNE is needed, and doctors 
should be able to furnish objective information about the effects, side effects, and individual differences in 
response to prescription drugs. Second, PNE users with an underlying mental disorder who receive no or only 
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insufficient treatment should be informed about further treatment options. Corporate interventions must be 
implemented if the mental disorder is associated with the workplace situation and job changeover is not desired. 
Third, workplace health promotion should address the issue of stress and successful coping strategies before 
PNE occurs. This goal could be achieved by strengthening the social and communication skills of the employees 
and management. Finally, future research should investigate differences between PNE users with and without a 
current or past mental disorder. The motives and profiles of “healthy” and more vulnerable PNE users likely 
differ and consequently require different intervention measures.  
 
Conclusions 
Our research constitutes the first comprehensive and representative large-scale study of PNE on a national level 
in Europe. Among the Swiss population, 4.0% reported lifetime PNE, but only 2.1% reported past-year PNE. 
Lifetime PNE was strongly associated with prior diagnosis of at least one mental disorder, with being a student 
rather than employed, and with illegal stimulant use experience. PNE is not (yet) common among the Swiss 
population, but monitoring further development is recommended. 
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Table 1 Studies estimating the prevalence of pharmacological neuroenhancement (PNE) published between 2000 and 2015; only PNE specific studies are included in the table. 
Please refer to Benson et al. [13] for a general overview of studies estimating the prevalence of nonmedical prescription stimulant misuse. 
 
Author (Year) Study sample Lifetime prevalence of PNE 12-month prevalence of PNE 
(or other if specified) 
Prevalence soft enhancement 
  Prescription drugs 
(nonmedical use) 
Recreational drugs 
(for enhancement) 
Prescription drugs 
(nonmedical use) 
Recreational drugs 
(for enhancement) 
Caffeine, food supplements, 
OTC-drugs 
Arria et al. (2013) [36] 984 U.S. college 
students 
38.0% stimulants to 
help study at least 
once in 4 years 
    
Castaldi et al. (2012) 
[14] 
77 Italian university 
students (limitation: 
unclear whether OTC 
drugs are included) 
16.0% – drugs to 
improve attention, 
cognitive performance 
or memory or to cope 
with fatigue and 
sleepiness 
 
 
  
DAK (2009) [30] 3017 German 
employees aged 20 to 
50 years old 
1.0% to 5.0% MPH, 
MOD, ATD, BB, or 
ADEM to improve 
performance at work 
 
2.2% regular users  
  
DAK (2015) [32] 5017 German 
employees aged 20 to 
50 years old 
6.7% MPH, MOD, 
ATD, BB, or ADEM 
to improve 
performance at work 
3.3% cognition 
4.7% mood and 
reduced nervousness 
 
 
4.2% regular users 
3.2% – all 
1.5% cognition 
2.1% mood and 
reduced nervousness 
 
  
DeSantis et al. (2008) 
[7] 
1811 U.S. college 
students 
23.2% stimulants to 
stay awake to study 
21.5% stimulants to 
concentrate on your 
work 
11.8% stimulants to 
help memorize 
Any purpose:  
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34.0% stimulants  
Dietz et al. (2013) [37] 2569 German 
university students  
 
20.0% – all (RRT) a 
 
Eickenhorst et al. 
(2012) [15] 
1218 German 
university students and 
106 German graduates 
7.0% illicit drugs – MPH, MOD, DEX, ATD, 
BB, COC, HER, or MDMA 
  
Lifetime  
89.3% COF 
c
 
25.2% HSED 
11.1% CAFT 
 
Forlini et al. (2014) 
[38] 
1026 German 
university students 
2.2% – drugs to 
enhance attention, 
endurance, and 
cognitive function  
3.8% CAN 
1.4% AMPH 
1.3% COC 
1.0% MDMA 
 
Lifetime 
55.9% COF 
40.8% ED 
Franke et al. (2011) 
[16,39] 
1035 German high 
school and 512 
German undergraduate 
university students 
1.3% stimulants – all 
 
 
2.6% illegal stimulants 
 
0.3% stimulants – all 
< 0.1% – all (30 d) 
 
1.0% illegal stimulants 
0.3% – all (30 d) 
 
Lifetime/12 m/30 d 
53.2%/8.5%/6.3% COF 
39.0%/10.7%/6.3% ED 
10.5%/3.8%/0.8% CAFT 
Franke et al. (2013) 
[40] 
1145 German 
surgeons 
8.9% illicit drugs – all (vs. 19.9% RRT) 
 
2.6% DEX 
2.5% MPH 
2.2% MOD 
2.4% ATD (vs. 15.1% RRT) 
1.6% COC 
1.2% EPH 
0.9% AMPH 
0.6% MDMA 
0.6% ATX 
0.3% ADEM 
3.0% illicit drugs – all 
1.4% illicit drugs – all (30 d) 
0.8% illicit drugs – all (7 d) 
 
1.0% ATD 
0.5% ATD (30 d) 
0.4% ATD (7 d) 
 
Franke et al. (2014) 3306 surgeons at 
international 
conferences 
  
Lifetime/12 m 
66.8%/61.9% COF 
24.2%/15.4% ED 
12.6%/5.9% CAFT 
30 d/7 d 
56.9%/50.5% COF 
9.9%/6.1% ED 
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4.7%/3.8% CAFT 
Gay et al. (2007) [41] 663 French employees 24.1% – all 7.5% ALC 
2.1% CAN 
  
Lifetime  
10.3% NIC 
Grebner et al. (2010) 
[31] 
1004 Swiss employees 
  
4.0% drugs to improve cognitive performance 
or mood at work 
10.0% drugs to relax or sleep after stress at 
work (to work better the next day) 
 
Mache et al. (2012) 
[42] 
1053 German 
university students 
1.0–13.0% illicit drugs – all 
15.0% CAN 
b
  
2.3% COC 
2.2% MPH 
2.0% BB 
1.0% MOD 
1.0% FLX 
0.1% PIR 
  
 
 
Lifetime 
22.0% HSED 
10.0% CAFT 
Maher et al. (2008) 
[25] 
1427 academics from 
60 countries 
20.0% – all 
 
12.4% MPH 
8.8% MOD 
6.0% DEX & other 
3.0% BB 
    
Maier et al. (2013) [20] 6275 Swiss university 
students 
7.8% – all  
4.1% MPH 
2.7% SED/SLP 
1.2% BB 
0.5% ATD 
0.3% MOD 
0.1% ADEM 
7.6% – all 
5.6% ALC 
2.5% CAN 
0.4% AMPH 
0.2% COC 
0.1% MDMA 
0%   GHB/GBL 
30 d prior to last exam 
2.6% MPH 
2.1% SED/SLP 
0.7% BB 
0.4% ATD 
0.2% MOD 
0.1% ADEM 
30 d prior to last exam 
5.1% ALC 
1.8% CAN 
0.3% AMPH 
0.1% COC 
0.02% MDMA 
0% GHB/GBL 
Lifetime/30 d prior to last 
exam 
53.2%/49.1% COF 
35.9%/29.7% ED 
18.2%/14.9% VT 
18.2%/13.2% HSED 
4.4%/2.6% CAFT 
Mazanov  et al. (2013) 
[43] 
1729 Australian 
university students 
1.9% MOD/RAC to 
study  
4.4% MPH/DEX to 
study 
1.5% SED to study 
4.5% illegal drugs to 
study 
  
Lifetime/ 
63.5% CAF 
22.0% OTC 
 
McNeil et al. (2011) 
[44] 
243 U.S. dental & 
dental hygiene 
8.2% stimulants to 
improve attention/ 
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students concentration 
1.6% stimulants for 
higher grades 
DEX > MPH 
Middendorff et al. 
(2012) [45] 
7989 German 
university students 
5.3% illicit drugs – all 
1.3% various drugs 
1.2% CAN 
1.0% MPH 
0.6% BB 
0.5% AMPH 
0.2% MOD 
0.2% COC 
0.1% MDMA 
  
Lifetime 
5.2% – all d 
4.3% HSED
 d
 
0.8% CAF 
d
 
 
Ott & Biller-Andorno 
(2014 ) [18] 
1765 Swiss university 
students 
4.7% ADHD drugs to 
help study 
MPH < MOD < DEX 
    
Partridge et al. (2012) 
[46] 
1265 Australian 
university students 
2.4% drugs to enhance 
concentration and 
alertness 
    
Prudhomme White et 
al. (2010) [47] 
1025 U.S. university 
students 
8.7% MPH to improve 
study habits 
3.2% MPH to improve 
grades 
Any purpose:  
16.2% stimulants 
    
Rosiers & Van Hal 
(2005) [17] 
1501 Flemish 
university and college 
students 
  
2.9% stimulants 
2.6% stimulants 
(exams) 
  
Sattler & Wiegel 
(2013) [48] 
5882 German 
university students  
4.6% drugs to enhance 
the cognitive 
efficiency  
 
3.2% – all 
2.3% – all (6 m) 
1.2% – all (30 d) 
  
Schelle et al. (2015) 
[49] 
1572 Dutch university 
students 
1.7% drugs to improve 
cognitive function 
1.3% illegal drugs 
1.8% ALC
 e
 
  
Lifetime 
45.6% – all e 
41.7% CAF 
9.0% OTC 
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3.0% NIC 
0.5% SMA
 f
 
Schilling et al. (2012) 
[50] 
6142 German 
participants (any) 
 
 1.5% illicit drugs – all 
1.2% ATD 
0.5% AMPH 
0.1% BB 
 
 
Singh et al. (2014) [33] 877 UK university 
students 
6.2% MOD 
4.0% MPH 
2.0% ADD 
   
Lifetime 
24.3% CAFT 
Teter et al. (2006) [51] 4580 U.S. college 
students 
5.4% stimulants to 
concentrate 
5.0% stimulants to 
study 
4.0% stimulants to 
increase alertness 
DEX > MPH 
Any purpose:  
8.3% stimulants 
 
Any purpose:  
5.9% stimulants – all 
4.5% DEX 
1.4% MPH 
 
  
Timmer et al. (2012) 
[52] 
422 Dutch 
psychiatrists and 
doctors working in 
psychiatry 
  
11.0% – all 
5.0% BZD 
4.0% BB 
2.0% MPH 
  
Wolff et al. (2014) [53] 1007 German 
university students 
5.8% – drugs to 
increase cognitive 
performance 
3.5% illegal drugs 3.0% – all 1.7% illegal drugs Lifetime/12 m 
83.2%/52.3% – all 
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a 
Including not only prescription and recreational drugs but also caffeine tablets and should, therefore, be interpreted carefully. 
b
 The study authors report themselves a prevalence 
of illicit drug use for PNE of 1.0-13.0% but cannabis use for PNE was reported by 15.0% of participants [42]. 
c
 Students reported also the use of the lifestyle drugs, alcohol 
(83.0%), nicotine (33.0%), and cannabis (14.0%) during their studies, which is not reported in the table, because it refers not to PNE use. 
d
 Post-coded (“other”) and, therefore, 
underestimated. 
e 
Alcohol was categorized as lifestyle drug together with nicotine and legally available OTC drugs similar to the category soft enhancement here. However, 
alcohol is not considered “soft” because the effects and consequences can be compared with those of illegal drugs that are used recreationally. f Legal available psychoactive 
substances that are sold in Smart shops. ADEM: anti-dementia drugs; ADHD: attention-deficit hyperactivity disorder; ALC: alcohol; AMPH: illegal amphetamine; ATD: 
antidepressants; ATX: atomoxetine; BB: beta-blockers; BZD: benzodiazepines; CAF: products containing caffeine; CAFT: caffeine tablets; CAN: cannabis; COC: cocaine; COF: 
coffee; DEX: dexamphetamine; ED: energy drinks; EPH: ephedrine; FLX: fluoxetin; GHB/GBL: gamma-hydroxybutyrate/gamma-butyrolactone; HER: heroine; HSED: herbal 
sedatives; MDMA: 3-4 methylenedioxymethamphetamine (ecstasy); METH: methamphetamine; MOD: modafinil; MPH: methylphenidate; NIC: nicotine; OTC: over-the-counter 
drugs; PIR: piracetam; RRT: randomized response technique; SED: sedative medication; SLP: sleeping pills; SMA: legal available products from smart shops; VT: vitamins and 
tonics. 
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Table 2 Participant characteristics of the study population with and without experience with PNE and the odds 
ratios (OR) for the univariate associations of each variable with lifetime PNE.  
 
  
Total  
N = 10 171 
PNE  
n = 411 
No PNE  
n = 9760 OR (95% CI)
 a
 P
 a
 
Sex  
      Male 
 
53.4% (5433) 3.7% (202) 96.3% (5231) 
  Female 
 
46.6% (4738) 4.4% (208) 95.6% (4529) 1.22 (1.00, 1.50) < .05 
Age group 
      15–24 years 
 
18.4% (1876) 5.5% (104) 94.5% (1772) 
  25–34 years 
 
21.1% (2144) 4.1% (88) 95.9% (2056) 0.73 (0.53, 0.99) .04 
35–44 years 
 
22.1% (2251) 3.9% (87) 96.1% (2164) 0.68 (0.50, 0.92) .01 
45–74 years 
 
38.3% (3899) 3.4% (132) 96.6% (3767) 0.58 (0.44, 0.77) < .01 
Linguistic region 
      German 
 
73.3% (7456) 3.8% (285) 96.2% (7171) 
  French 
 
22.6% (2302) 5.0% (115) 95.0% (2187) 1.36 (1.09, 1.71) < .01 
Italian 
 
4.0% (412) 2.4% (10) 97.6% (402) 0.61 (0.32, 1.15) .13 
Professional activity 
      In education 13.5% (1375) 6.8% (93) 93.2% (1282) 
  Full-time work ≥ 90% 54.6% (5553) 3.3% (182) 96.7% (5371) 0.45 (0.35, 0.60) < .01 
Part-time work < 90% 31.9% (3243) 4.2% (135) 95.8% (3107) 0.59 (0.45, 0.79) < .01 
Monthly income b       
< 6000 CHF  25.2% (2025) 6.0% (122) 94.0% (1903)   
6000-10 000 CHF  44.2% (3547) 3.3% (117) 96.7% (3430) 0.54 (0.42, 0.71) < .01 
> 10 000 CHF  30.6% (2454) 3.6% (89) 96.4% (2366) 0.58 (0.43, 0.77) < .01 
Relationship       
None/temporary  27.4% (2788) 5.5% (152) 94.5% (2636)   
Stable  72.6% (7383) 3.5% (259) 96.5% (7124)  0.61 (0.50, 0.75) < .01 
Children at home < 18       
None  64.2% (6534) 4.6% (299) 95.4% (6235)   
At least one  35.8% (3636) 3.1% (111) 96.9% (3525) 0.67 (0.54, 0.84) < .01 
Perceived health  
SF-12, scale 1–5   3.49 (0.79)  3.04 (0.87) 3.50 (0.79) 0.46 (0.40, 0.52) < .01 
Stress (12 m)  
SECO, scale 1–5   3.22 (0.94) 3.81 (0.95) 3.20 (0.93) 2.06 (1.84, 2.31) < .01 
Psychological consulting       
Never  79.6% (8091) 1.9% (156) 98.1% (7935)   
At least once  20.4% (2080) 12.3% (255) 87.7% (1825) 7.36 (6.00, 9.08) < .01 
Mental disorder c       
Never  78.4% (7970) 1.5% (118) 98.5% (7852)   
At least one  21.6% (2201) 13.3% (293) 86.7% (1908) 10.26 (8.20, 12.83) < .01 
Data are % (number) or mean (standard deviation) adjusted for age, gender, and language region. 
a
 Population-
based weights were removed in the regression analyses. 
b
 No information provided by n = 2144, all other 
variables complete. 
c 
ADD/ADHD, narcolepsy, depression, anxiety disorder, dependency (lifetime diagnosis). 
PNE: pharmacological neuroenhancement; SF-12: The 12-Item Short Form Health Survey; SECO: State 
Secretariat for Economic Affairs. 
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Table 3 Lifetime use of legal and illegal drugs and potential soft enhancers in the sample and the odds ratios 
(OR) for the univariate associations of substance use with lifetime PNE. 
 
 
Total  
N = 10 171 
PNE   
n = 411 
No PNE  
n = 9 760 OR (95% CI)
 a
 P
 a
 
Lifetime drug use  
 
    
Alcohol  93.8% (9541) 95.0% (390) 93.8% (9151) 1.30 (0.82, 2.09) .26 
Tobacco 63.2% (6424) 76.2% (313) 62.6% (6111) 1.86 (1.47, 2.36) < .01 
Cannabis  32.1% (3261) 51.5% (211) 31.2% (3050) 2.36 (1.93, 2.89) < .01 
Cocaine  3.7% (378) 17.6% (72) 3.1% (306) 6.65 (5.02, 8.82) < .01 
MDMA (ecstasy) 2.7% (274) 12.8% (52) 2.3% (221) 6.44 (4.65, 8.92) < .01 
Illegal amphetamine  2.0% (207) 12.5% (52) 1.6% (155) 8.77 (6.25, 12.32) < .01 
GHB/GBL 0.6% (60) 3.2% (13) 0.5% (46) 6.83 (3.58, 13.04) < .01 
Ketamine  0.2% (21) 2.4% (10) 0.1% (11) 20.40 (8.41, 49.53) < .01 
Caffeine products
 b
 92.8% (9439) 93.2% (383) 92.8% (9057) 1.04 (0.70, 1.55) .86 
Vitamins & OTC drugs
 c
 46.0% (4673) 63.4% (260) 45.2% (4413) 2.16 (1.75, 2.67) < .01 
Fictitious drugs
 d
 0.2% (25) 1.0% (4) 0.2% (21) 3.51 (1.04, 11.80) .04 
Data are % (number) adjusted for age, gender, and language region. 
a 
Population-based weights were removed in 
the regression analyses. 
b
 Coffee, caffeine tablets, and energy drinks. 
c 
Herbal sedatives, vitamins, and tonics. 
d
 
Supraval® and Energyl®. PNE: pharmacological neuroenhancement; OTC: over-the-counter. 
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Table 4 Odds ratios (OR) for the overall model of the multivariable associations ( fully adjusted results) between 
participant characteristics and lifetime PNE. 
 
 
OR (95% CI)
 
 P
 
 
Sex  
 
 
Male 0.78 (0.59, 1.03) .08 
Female 
 
 
Age group 
 
 
15-24 years 
 
 
25-34 years 1.14 (0.69, 1.89) .60 
35-44 years 1.33 (0.77, 2.30) .31 
45-74 years 0.88 (0.52, 1.47) .62 
Professional activity 
 
 
In education 
 
 
Full-time work ≥ 90% 0.35 (0.21, 0.57) < .01 
Part-time work < 90% 0.39 (0.23, 0.67) < .01 
Monthly income a   
< 6,000 CHF   
6,000-10,000 CHF 0.90 (0.66, 1.22) .50 
> 10,000 CHF 1.11 (0.79, 1.57) .54 
Relationship   
None/temporary   
Stable 1.02 (0.77, 1.37) .87 
Children at home < 18   
None   
At least one 0.67 (0.50, 0.91) .01 
Perceived health  
SF-12, scale 1-5 0.76 (0.64, 0.90) < .01 
Stress (12 m)  
SECO, scale 1-5 1.51 (1.31, 1.75) < .01 
Psychological consulting   
Never   
At least once 2.54 (1.90, 3.42) < .01 
Mental disorder
 b   
Never   
At least one 4.26 (3.14, 5.80) <.01 
Lifetime drug use   
Alcohol 0.98 (0.55, 1.75) .95 
Tobacco 1.16 (0.85, 1.58) .37 
Cannabis  1.20 (0.89, 1.61) .22 
Cocaine  2.40 (1.51, 3.82) < .01 
MDMA (ecstasy) 1.48 (0.85, 2.56) .17 
Illegal amphetamine  2.44 (1.37, 4.33) < .01 
Ketamine  2.64 (0.88, 7.87) .08 
GHB/GBL 1.54 (0.58, 4.08) .39 
Population-based weights were removed in the regression analyses. 
a 
ADD/ADHD, narcolepsy, depression, 
anxiety disorder, dependency (lifetime diagnosis). SF-12: The 12-Item Short Form Health Survey; SECO: State 
Secretariat for Economic Affairs. N = 10 084. R
2 = .08 (Cox & Snell), .27 (Nagelkerke). Model χ2 (22) = 
648.846, P < .001. 
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Table 5 Prevalence of nonmedical prescription drug use for PNE in the study population (N = 10 171), main 
source of supply, and whether the expectations of use were fulfilled. 
 
 
LTP 12-MP 30-DP 
Main source of 
supply 
Expectations 
fulfilled 
Nonmedical prescription drug 
use 
   
  
Tranquilizers 1.06% (108) 0.59% (60) 0.40% (40) Doctor 53.7% (58) 73.5% (79) 
Antidepressants 0.81% (83) 0.37% (38) 0.18% (18) Doctor 73.8% (61) 70.8% (59) 
ADD/ADHD medication 0.57% (58) 0.29% (29) 0.07% (7) Friend 55.8% (32) 61.0% (35) 
Beta-blockers 0.14% (14) 0.04% (4) 0.04% (4) Doctor 52.8% (8) 72.4% (10) 
Modafinil 0.07% (7) 0.04% (4) 0.02% (2) Friend 31.0% (2)  31.6% (2) 
Anti-dementia drugs 0.02% (2) 0 0 Doctor 100.0% (2) - 
Data are % (numbers) adjusted for age, gender, and language region. LTP: lifetime prevalence; 12-MP: 12-
month prevalence; 30-DP: 30-day prevalence. 
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Table 6 Prevalence of PNE motives (M1-M4) among participants who were experienced with alcohol and illegal 
drug use for a set of multiple-answer options. 
 
 
M1.  
PCE (attention, 
concentration, 
memory) 
M2.  
Reduction of 
nervousness/st
age fright 
M3.  
PME at 
work/for 
studying 
M4.  
Relaxation after 
stress at 
work/education 
Lifetime drug use     
Alcohol, n = 9 541 0.2% (20) 2.4% (233) 0.6% (60) 25.4% (2428) 
Cannabis, n = 3261 1.0% (33) 2.4% (78) 1.3% (41) 17.4% (568) 
Cocaine, n = 378 11.6% (44) 2.0% (8) 1.0% (4) 5.7% (22) 
MDMA (ecstasy), n = 274 3.0% (8) 1.1% (3) 0.3% (1) 6.1% (17) 
Illegal amphetamine, n = 207 15.2% (31) 2.9% (6) 2.1% (4) 4.5% (9) 
GHB/GBL, n = 60 0 0 0 2.3% (1) 
Ketamine, n = 21  5.1% (1) 4.3% (1) 5.1% (1) 0 
Data are % (number) adjusted for age, gender, and language region. PCE: pharmacological cognitive 
enhancement; PME pharmacological mood enhancement. 
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Figures 
Figure 1 Flowchart of the sample composition using the Internet panel of the LINK institute in Switzerland 
 
• 39 996 invitations 
• 4590 direct participation (11.4%)  
• 12 224 after the 1st reminder (30.6%) 
• 1 280 after the 2nd reminder (3.2%)  
18 094 
• 2155 Quota-Overflow (11.9%) 
• 3535 Screen-Out (19.5%) 
12 404 
• 2320 Dropout 
(18.7%) 
10 084 
